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BACKGROUND & AIMS: To influence host and disease pheno-
type, compositional microbiome changes, which have been
demonstrated in patients with primary sclerosing cholangitis
(PSC), must be accompanied by functional changes.We therefore
aimed to characterize the genetic potential of the gutmicrobiome
in patients with PSC compared with healthy controls (HCs) and
patients with inflammatory bowel disease (IBD). METHODS:
Fecal DNA from 2 cohorts (1 Norwegian and 1 German), in total
comprising 136 patients with PSC (58% with IBD), 158 HCs,
and 93 patients with IBD without PSC, were subjected to
metagenomic shotgun sequencing, generating 17 billion paired-
end sequences, which were processed using HUMAnN2 and
MetaPhlAn2, and analyzed using generalized linear models and
random effects meta-analyses. RESULTS: Patients with PSC had
fewer microbial genes compared with HCs (P < .0001).
Compared with HCs, patients with PSC showed enrichment and
increased prevalence of Clostridium species and a depletion of,
for example, Eubacterium spp and Ruminococcus obeum. Patients
with PSC showed marked differences in the abundance of genes
related to vitamin B6 synthesis and branched-chain amino acid
synthesis (Qfdr< .05). Targeted metabolomics of plasma from an
independent set of patients with PSC and controls found reduced
concentrations of vitamin B6 and branched-chain amino acids in
PSC (P < .0001), which strongly associated with reduced liver
transplantation–free survival (log-rank P< .001). No taxonomic
or functional differences were detected between patients with
PSC with and without IBD. CONCLUSIONS: The gut microbiome
in patients with PSC exhibits large functional differences compared
with that in HCs, including microbial metabolism of essentialnutrients. Alterations in related circulating metabolites associated
with disease course, suggesting that microbial functions may be
relevant for the disease process in PSC.
Keywords: Microbiome; Primary Sclerosing Cholangitis; Vitamin
B; Branched Chain Amino Acids.
rimary sclerosing cholangitis (PSC) is a chronicPprogressive cholestatic liver disease of unknown eti-
ology, characterized by multifocal inflammation and fibrosis
of the biliary tree.1 Up to 80% of patients with PSC are
diagnosed with concomitant inflammatory bowel disease
(IBD), thus PSC is a prototypical disease of the gut–liver axis.
Compositional changes in the fecal bacterial microbiome
of patients with PSC have been reported in several cross-
sectional studies.2–5 Changes are also present in pediatric
patients,6 but so far there are few established links between
the gut microbiome and severe disease or late-stage disease
like cirrhosis.7 There are also disturbances in other
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Previous studies have identified large compositional
differences in the gut microbiome of PSC patients and
controls.
NEW FINDINGS
We identify several species-level differences in addition to
large functional differences in the genetic composition of
the gut microbiome between PSC patients and controls,
especially genes related to microbial metabolism of
essential nutrients, which could potentially be linked to
disease progression.
LIMITATIONS
Cohort size, although the largest study of the microbiome
in PSC utilizing full metagenomic sequencing published
so far. No inclusion of samples from other liver diseases
as additional disease controls, or matched blood and
stool samples.
IMPACT
Altered functional status of the microbiome in PSC may
be relevant for the disease course, and could thus also
potentially be a new treatment target.

















important members of the microbiome, like fungi, and the
interplay between these microbial communities.4 These
data are all cross-sectional, limiting the possibility for con-
clusions on causality.
In mouse models, inducing a germ-free state can either
improve or worsen the biliary disease, depending on disease
mechanisms.8,9 In humans, trials with antibiotics improved
liver biochemistry in PSC,10 but a pilot trial of fecal micro-
biota transplantation was too small to allow any firm con-
clusions.11 Furthermore, specific bacteria found in human
PSC stool can modify experimental biliary disease in mice.12
Overall, both human and experimental evidence suggest that
gut microbes can act as disease modifiers in PSC. The
mechanisms underlying these effects are so far not known,
but current data suggest that altered bile acid homeostasis,
increased bacterial translocation, or uncharacterized im-
mune alterations could be relevant.7–10
A major limitation of the available data in PSC is the lack
of microbe identification on the species level when using
16S ribosomal RNA gene sequencing. Furthermore, one
important possibility is that bacterial functions and the by-
products of their activity, for example, metabolites, could be
more important than the composition of the microbiome.
The majority of compounds entering the body through the
oral route may potentially be metabolized by gut microbes,
resulting in a large number of microbial by-products
entering the circulation of the host, potentially affecting
human organs. One example for such a modified metabolite
is the bacteria-dependent metabolite trimethylamine-N-
oxide, which has been associated with reduced liver
transplantation–free survival.13 Both species-level identifi-
cation and quantification of the bacterial functional poten-
tial can be analyzed using full shotgun metagenomic
sequencing. The aim of our study was to apply large-scalemetagenomic sequencing in 2 independent cohorts of pa-
tients with PSC to define which species are associated with
PSC, and whether specific microbial functions are altered,




We collected fecal samples from nontransplanted patients
with PSC from 2 independent cohorts published previously.14
The Norwegian cohort was included in the Norwegian PSC
Research Center Biobank at Oslo University Hospital, and pa-
tients with PSC in the German cohort were recruited at the
University Medical Center Hamburg-Eppendorf. The diagnosis
of PSC was made in accordance with clinical guidelines and
typical findings on cholangiography or liver biopsy, and all
patients with PSC had undergone screening for IBD.15,16 Plasma
samples from 191 Norwegian patients with PSC and 48 controls
(collected 2008–2015) were included for analysis of metabo-
lites and survival from sample date to liver transplantation or
death. For an overview of the cohorts and the study design, see
Supplementary Figure 1.
Norwegian healthy population controls were randomly
selected from donors registered in the national Norwegian
Bone Marrow Donor Registry (Oslo, Norway), and German
healthy controls (HCs) were recruited through the PopGen
Biobank17 and the FoCus cohort.18
Norwegian patients with IBD without a medical history of
liver disease, and in clinical remission were recruited in an
outpatient setting from Oslo University Hospital (Oslo, Norway).
German patients with IBD included as part of the KINDRED
program were recruited through the PopGen Biobank. IBD
diagnosis was based on colonoscopy and histology and accepted
criteria.19,20 Routine biochemical parameters for all participants
were retrieved through hospital databases and the respective
biobank databases. Mayo risk scores were calculated using the
algorithm for the revised Mayo risk score,21 and the Amsterdam-
Oxford model for PSC was calculated according to the original
formula.22 Transient elastography measurements were obtained
with Fibroscan (Echosens, Paris, France) and enhanced liver
fibrosis score calculated as described previously.23
Ethics
The study was performed in accordance with the Declara-
tion of Helsinki. Written informed consent was obtained from
all study participants. Ethical approval was obtained from the
respective Local Ethics Committees (Norway, Regional Com-
mittee for Medical and Health Research Ethics in South-Eastern
Norway, reference 2015/2140; Germany, Hamburg, reference
MC-111/15; Kiel, reference A148/14, A117-13, A156-03). All
authors had access to the study data and reviewed and
approved the final manuscript.
Fecal Sample Collection, DNA Extraction, and
Exclusion Criteria
Fecal samples were collected and DNA extracted as
described previously (see Supplementary Material for de-
tails).2,14 All participants with previous bowel resection, small-
duct PSC, other chronic liver diseases, a gastrointestinal stoma,




BILIARYor who were exposed to antibiotics in the 6 weeks preceding
sampling were excluded.
Metagenome Library Preparation, Sequencing,
and Quantitative Real-Time Polymerase Chain
Reaction
Quality and quantity of DNA samples were determined us-
ing Qubit measurements and the Genomic DNA ScreenTape
(Agilent, Santa Clara, CA). Subsequently, metagenomic library
preparation was performed as described previously by using
Illumina Nextera DNA Library Preparation Kit (Illumina, San
Diego, CA).24 Sequencing was performed with 2  125 bp on a
HiSeq 2500 platform (Illumina; German HCs and all Norwegian
samples) or with 2  150 bp on a HiSeq 4000 platform (Illu-
mina; German patients with PSC and IBD). Primers for quan-
titative real-time polymerase chain reaction are given in
Supplementary Table 1 and further details can be found in
the Supplementary Methods.
Post-Sequencing Processing
Quality control and filtering of the raw reads was done with
KneadData (version 0.7.0), and Bowtie2 (version 2.3.4.2).
Taxonomic and functional profiling was performed using
HUMAnN2 (version 0.11.2),25 incorporating MetaPhlAn226
(version 2.7.8), and DIAMOND (version 0.8.38). Additional de-
tails on bioinformatic handling can be found in the
Supplementary Material.
Plasma Metabolites
All analyses of metabolites in plasma were performed at
Bevital (Bergen, Norway). Vitamers were analyzed by liquid
chromatography-tandem mass spectroscopy,27 whereas amino
acids and related metabolites were analyzed by gas
chromatography-tandem mass spectroscopy.28
Statistical Analysis
Comparison of categorical variables was performed using
the c2 test, or Fisher exact test, where appropriate, and the
Cochran–Mantel–Haenszel test across cohorts. Mann-Whitney
U test was applied for continuous clinical variables, metab-
olomic data, and analysis of gene-family–based a-diversity
measures. When adjusting for clinical covariates in analyses of
gene richness, linear regression was used. Kaplan-Meier plots
with log-rank test and Cox proportional hazards regression
analyses were used to investigate associations with end points
(death or liver transplantation); all analyses were perfomed in
SPSS (version 25; IBM, Armonk, NY). Microbiome co-
correlation networks were made using R (version 3.6.1) us-
ing the SparCC algorithm with correlations cutoffs set at r >
0.40 and unadjusted P < .05. b-diversity analyses (noncon-
strained ordination of genus-level Bray-Curtis dissimilarities)
were performed via permutational multivariate analysis of
variance using the “vegan” package in R with 10,000 permu-
tations. For correlation analyses, Spearman’s rank correlation
test was used. Analyses of differential abundance of single taxa
and functional features (enzyme families; level-4 Enzyme
Commission [EC] categories), Kyoto Encyclopedia of Genes and
Genomes ontology and MetaCyc pathways) were first per-
formed within each country, including age, body mass index,
and sex as covariates in the model unless otherwise stated,
followed by a meta-analysis. Samples with missing informationfor covariates were excluded from the analyses. A generalized
model with zero-inflated beta distribution was fitted using the
R package “GAMLSS” (additional details in Supplementary
Methods). Lastly, a random effects meta-analyses was then
performed using the R package “metamicrobiomeR,” allowing
for variance in the effect sizes between the 2 cohorts, using
the estimates and standard errors from the per-country ana-
lyses described above. An overview of the main health state
and drug use comparisons analyzed (g1–g9) can be found in
Supplementary Table 2. False discovery rate was calculated
according to Benjamini-Hochberg, false discovery rate–
corrected P values were denoted as Qfdr. The machine-
learning procedure random forest (“randomForest” package
in R) was used to predict phenotypes based on the meta-
genome data. The cohorts were randomly split into training
and prediction sets with a ratio of 8:2, or one country used for
training and the other for prediction, and the procedure was
repeated 100 times for each prediction task. Comparison of
predicted outcomes was summarized with area under the
receiver operating characteristic curve (AUC), Matthew’s cor-
relation coefficient, and F1 measure. For additional details see
the Supplementary Material.
Results
After sequencing and quality control of 17 billion paired-
end sequences, 5.5 terabytes of data were available for
analysis from 387 individuals; in total 136 patients with
PSC, 158 HCs, and 93 IBD controls (Table 1, Supplementary
Tables 3 and 4).
Overall Microbial Taxonomic and Genetic
Diversity
The overall microbiome composition showed significant
shifts among phenotypes (PSC, HCs, and IBD) in the merged
cohort (Figure 1A), which was also apparent when analyzing
each cohort separately (Figure 1B and C). Geography was
also an important factor for the overall microbiome
composition for all phenotypes (Figure 1A), including HCs
(Supplementary Figure 2).
Patients with PSC had markedly reduced microbial gene
richness (observed genes) compared with HCs (Figure 1D),
also when adjusting for age, sex, and body mass index
(linear regression, P < .016, P ¼ .001, and P < .0001 in the
German, Norwegian, and merged cohort, respectively).
Concomitant IBD had no effect on gene richness in patients
with PSC (Supplementary Figure 3).
Individual Species
After quality control and filtering, a total of 413 taxa
were identified in the full dataset (phylum to strain level).
For each country, single taxa with <80% zeros across
samples were analyzed both for a shift in distribution (mu)
and a difference in zero abundance (nu). The analysis
identified an enrichment of Clostridium asparagiforme and
an unclassified Escherichia species in PSC compared with
HCs, as well as a marked depletion of several species, for
example, Ruminococcus obeum, Eubacterium siraeum, and
Eubacterium rectale (meta-analyses Qfdr < .05, Figure 2A).
Furthermore, 9 species showed an increased prevalence,
Table 1.Summary of Primary Sclerosing Cholangitis and Healthy Control Characteristics in the Study Cohorts
Characteristics
German cohort Norwegian cohort PSC G vs N HC G vs N
PSC (n ¼ 67) HC (n ¼ 120) P value PSC (n ¼ 69) HC (n ¼ 38) P value P value P value
Age, y 47.0 (17 to 74) 46.5 (21 to 72) .353 48.0 (21 to 69) 47.0 (35 to 61) .852 .880 .269
Sex, male 43 (64.2) 53 (44.2) .010 45 (65.2) 24 (63.2) .836 1.000 .064
BMI, kg/m2a 23.7 (15.7 to 32.9) 23.6 (19.0 to 42.7) .893 25.1 (17.7 to 36.9) 26.0 (19.4 to 39.4) .654 .003 .013
Smoking, yes 11 (16.4) 48 (40.0) <.001 1 (1.4) 6 (15.8) .008 .002 .011
AB last 6 mo, yesb 16 (23.9) NA — 8 (11.6) 5 (13.2) 1.000 .098 —
IBD, yes 33 (49.3) 0 — 46 (66.7) 0 — .060 —
Ulcerative colitis, yes 32 (47.8) — 36 (52.2) — .730
Crohn’s disease, yes 1 (1.5) — 10 (14.5) — .009 Available for
n in G/N
Medication, yes — — —
PPI 0 — 2 (2.9) — .500 67/69
Statins NA — 0 — — 67/69
UDCA 63 (94.0) — 23 (33.3) — <.001 60/69
Prednisolone/cortisone 13 (19.4) — 9 (13.0) — .420 60/69
5-ASA 29 (43.3) — 29 (42.0) — 1.000 61/69
Infliximab 2 (3.0) — 1 (1.4) — .614 60/69
Azathioprine 9 (13.4) — 9 (13.0) — 1.000 60/69
Budesonide 4 (6.0) — 3 (4.3) — .709 57/69
PSC-specific variables — — — —
PSC duration, y 7.0 (1.0 to 35.0) — 9.5 (1.6 to 31.7) — .057 61/69
IBD duration, y 15.0 (1.0 to 40.0) — 14.2 (1.2 to 44.5) — .610 31/41
Other autoimmune disease, yes NA — 18 (26.1) — 0/64
Mayo risk score NA — –0.07 (–1.92 to 3.33) — 0/51
Cirrhosis, yes 3 (4.5) — NA — 67/0
P-ANCA–positive NA — 26 (37.7) — 0/35
Creatinine, mmol/L NA — 68.0 (42.0 to 100.0) — 0/63
Bilirubin, mmol/L 10.3 (3.42 to 34.2) — 13.0 (5.0 to 114.0) — .007 43/62
Albumin, g/L NA — 43.0 (16.0 to 47.0 — 0/58
AST, U/L NA — 42.0 (18.0 to 197.0) — 0/58
ALT, U/L 37.5 (11.0 to 286.0) — 51.0 (14.0 to 331.0) — .021 44/63
ALP, U/L 117.0 (44.0 to 590.0) — 152.5 (30.0 to 598.0) — .004 44/62
GGT, U/L NA — 165.0 (12.0 to 1576.0) — 0/61
NOTE. Demographics for IBD controls are provided in Supplementary Table 4. None of the HCs used any of the stated medications. Continuous data given as median
(minimum to maximum), count data as n (%).
AB, antibiotics; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; G, German cohort; GGT, gamma-
glutamyltransferase; N, Norwegian cohort; NA, not available; PPI, proton pump inhibitors; 5-ASA, 5-aminosalicylic acid.
aBMI data missing for 10 HCs in the German cohort, other data complete unless otherwise stated.











Figure 1. Overall bacterial taxonomic
composition and gene richness in
patients with PSC and controls. Non-
constrained ordination of genus-level
Bray-Curtis dissimilarities in the micro-
biome of (A) patients with PSC, as well
as healthy and IBD controls, in the
merged cohort, and in the (B) the
German and (C) the Norwegian cohorts
separately, showing shifts in the global
microbiome composition. (D) Number of
observed genes in PSC compared with
controls. All group centroids in (A–C)
represent the arithmetic mean of the
groups’ respective points in the ordina-
tion, ellipses represent 95% confidence
level of the multivariate t-distributions.
Red horizontal bar in (D) represents the
median. GER, Germany; MDS, multiple
dimension scale; NOR, Norway.




BILIARYand we identified 5 species with lower prevalence in pa-
tients with PSC compared with HCs (Figure 2B). Although
several species showed similar patterns in IBD, species like
Ruminococcus obeum, Bacteroides intestinalis, and severalClostridium species did not differ between IBD and HCs
(Supplementary File 1).
Previous works have found increased levels of the Veil-
lonella genus in PSC.7 Veillonella atypica, Veillonella parvula,
Figure 2. Differences in species composition in PSC compared with HCs. (A) Species that were differently abundant and (B)
species with different prevalence in PSC and HCs. Species are colored by phyla affiliation. (C) Bacterial abundance co-
correlation network in HCs and (D) patients with PSC. In (A) and (B) the triangle/bar in the forest plot indicate log(odds ra-
tio)/SE. Red and blue lines in (C) and (D) indicate positive and negative correlations between species, respectively. Node size
reflects the square-root–transformed median relative abundances in each phenotype, and encircled nodes mark articulations
points. Only correlations with r > 0.4 are shown, and increasing correlation coefficient are reflected by increasing line
thickness. *Qfdr < .05; **Qfdr < .005; ***Qfdr < .0005.

















and an unclassified Veillonella species showed trending
increased prevalence in patients with PSC compared with
HCs (meta-analyses P ¼ .0062, P ¼ .026, and P ¼ .025,
respectively, Qfdr ¼ .058, Qfdr ¼.14, and Qfdr ¼ .14, respec-
tively, Supplementary Figure 4 and Supplementary File 1).
Other PSC-related species include K pneumoniae, in additionto Proteus mirabilis and Enterococcus gallinarum, previously
linked to intestinal barrier function and immune responses
in PSC.12 K pneumoniae was left out from our initial analysis
due to low abundance in the Norwegian cohort (see Mate-
rials and Methods). A targeted analysis detected K pneu-
moniae in the microbiome of 25% of patients with PSC, but




BILIARYonly in 4.4% of the HCs (Cochran–Mantel–Haenszel test, P <
.001). K pneumoniae was detected in the microbiome of
45.2% of IBD controls (Cochran–Mantel–Haenszel test, P ¼
.0057 vs PSC). E gallinarum and P mirabilis were detected in
only a few patients (Supplementary Table 5). When
applying a species-specific real-time polymerase chain re-
action on a subset of the German samples (PSC n ¼ 36, HCs
n ¼ 20, IBD n ¼ 17), K pneumoniae showed similar preva-
lence in PSC, IBD, and HCs (77.8%, 94.1%, and 75.0%,
respectively, Supplementary Figure 5A). E gallinarum and P
mirabilis were detected in a minority of samples
(Supplementary Figure 5B and C).
To further delineate structural microbiome differences
between the phenotypes, we generated bacterial species
abundance co-correlation networks using SparCC.29 The
network in HCs consisted of several large and small clusters
(Figure 2C). When overlaying the co-correlations observed
in PSC, there was a disruption of the network seen in the
HCs in the patients with PSC, with loss of several clusters
and fewer co-correlations in others (Figure 2D). IBD con-
trols without PSC also showed a disrupted network
compared with HCs, but markedly different from what was
observed in PSC (Supplementary Figure 6).Extensive Alterations in the Genetic Landscape of
the Microbiome in Primary Sclerosing
Cholangitis, Highlighting Changes in
Biosynthesis of Amino Acids and B Vitamins
In total, after filtering we detected 121 metabolic path-
ways (MetaCyc pathways) and 424 enzyme families present
in both cohorts. We identified 53 metabolic pathways
differentially abundant in the microbiomes of patients with
PSC compared with HCs, in addition to 106 enzyme families
(all meta-analyses Qfdr < .05, Figure 3 and Supplementary
File 1, respectively).
The microbiome of patients with PSC showed a marked
depletion of the metabolic pathway related to the biosyn-
thesis of the branched-chain amino acid (BCAA) isoleucine
(Figure 3), as well as several enzyme families related to the
BCAAs isoleucine, valine, and leucine compared with HCs
(Figure 4A–C and Supplementary File 1), and levels in pa-
tients with IBD were similar to levels in PSC. There were
also differences in metabolic pathways related to biosyn-
thesis of aromatic amino acids, but less consistent, with
some pathways enriched in PSC (PWY6628 superpathway
of L-phenylalanine biosynthesis) and others depleted, for
example, COMPLETE ARO-PWY superpathway of aromatic
amino acid biosynthesis, as seen in Figure 3. Four of the 7
most highly enriched metabolic pathways in PSC compared
with HCs were related to biosynthesis of 2 other amino
acids, that is, arginine and ornithine (Figure 3). These 4
pathways had similar levels in PSC and IBD, but in direct
comparisons only 2 of these pathways were significantly
enriched in IBD compared with HCs (Supplementary File 1).
Patients with PSC showed higher levels of metabolic
pathways related to biosynthesis of thiamine (vitamin B1)
compared with HCs (eg, THISYN-PWY superpathway of
thiamin diphosphate biosynthesis I, Figure 3). This pathwayshowed similar levels in PSC and IBD, while patients with
IBD showed higher levels compared with HCs
(Supplementary File 1). However, 3 metabolic pathways for
biosynthesis of 5’-phosphoribosyl-5-aminoimidazole
(PWY6122, PWY6277, and PWY6121), a key intermediate
in the biosynthesis of thiamine (vitamin B1), were all
depleted in PSC (Figure 3). Furthermore, patients with PSC
showed marked differences compared with HCs of several
enzyme families related to vitamin B6 metabolism, most
prominent was a marked depletion of EC4.3.3.6 pyridoxal-5-
phosphate synthase (Figure 4D), an enzyme that alone
constitutes the metabolic pathway pyridoxal 5’-phosphate
biosynthesis II and the predominant biosynthetic route for
the de novo production of the active form of vitamin B6,
pyridoxal 50-phosphate (PLP),30 and EC2.6.1.52 phospho-
serine transaminase (Supplementary File 1). The latter is 1
of 7 enzyme families comprising the metabolic pathway
PYRIDOXSYN-PWY: pyridoxal 50-phosphate biosynthesis I,
which was increased in PSC compared with HCs (Figure 3).
As for the last 6 enzyme families in this metabolic pathway,
1 (EC1.1.1.290) was enriched in PSC compared with HCs, 3
showed similar levels (EC2.6.99.2, 1.1.1.262 and 2.2.1.7),
and the last 2 (EC1.2.1.72 and 1.4.3.5) did not pass our
initial filtering (Supplementary File 1). A total of 84 species
contributed to EC4.3.3.6 pyridoxal-5-phosphate synthase in
the dataset (Supplementary File 2). E rectale and Eubacte-
rium siraeum, which were both depleted in PSC compared
with HCs in the meta-analyses (see Figure 2A), were among
the top 5 species contributing to the abundance of this
enzyme. Twenty-eight species contributed to PYRIDOXSYN-
PWY: pyridoxal 5’-phosphate biosynthesis I (Supplementary
File 2), but none of the contributing species detected in the
metanalysis showed a difference between PSC and HCs (all
Bacteroides, Qfdr > .30, Supplementary File 2).
Regarding other B vitamins, 2 enzymes, EC2.7.1.26
riboflavin kinase and EC2.7.7.2 flavin adenine dinucleotide
synthetase, responsible for synthesis of the active forms of
vitamin B2 (flavin mononucleotide and flavin adenine
dinucleotide, respectively), were also reduced in PSC
(Figure 4E and F), and riboflavin synthase (EC2.5.1.9),
which is responsible for a reaction resulting in synthesis of
riboflavin and 5-amino-6-D-ribitylaminouracil, was enriched
in PSC (Figure 4G). Furthermore, the microbiome of patients
with PSC showed increased abundance of enzyme families
related to ammonia production (Figure 4H and I). Enzyme
families related to antibiotic resistance like EC3.5.2.6 b-
lactamase were also enriched in PSC compared with HCs
(Figure 4J).Metabolic Pathways Diminished in the
Microbiome of Patients With Primary Sclerosing
Cholangitis Show Low Levels of Related
Metabolites in Plasma
As the initial microbiome analyses identified potential
alterations in bacterial metabolism of both BCAAs and B
vitamins, and the gut microbiome could be an important
source of these metabolites,31,32 we investigated selected
vitamin B and BCAA metabolites in plasma from another
Figure 3. Alterations in metabolic pathways in the microbiome of PSC. Heatmap and forest plot showing significant differences
in microbiome metabolic pathways (MetaCyc pathways, Qfdr < .05) between PSC and HCs from the individual cohorts (2 left
columns in the heatmap) and the meta-analysis (right column in the heatmap and the forest plot). Triangle/bar in forest plot
indicate log(odds ratio)/SE. *Qfdr < .05; **Qfdr < .005; ***Qfdr < .0005.

















cohort of 191 patients with PSC (27 were also recruited in
the metagenome study cohort) and 48 HCs (see
Supplementary Figure 1). The main active form of vitamin
B6, PLP, and the BCAAs isoleucine, leucine, and valine were
clearly reduced in plasma of patients with PSC compared
with HCs (Figure 5A–D). Other vitamin B6 metabolites (ie,
pyridoxal and 4-pyridoxic acid) were also lower in PSC
compared with controls (Supplementary Figure 7).
Furthermore, the vitamin B2 (riboflavin) metabolite flavin
mononucleotide showed reduced levels in PSC corre-
sponding to the reduction in EC2.7.1.26, and there was no
difference for vitamin B2 itself (Supplementary Figure 8A
and B). For vitamin B1, thiamine was similar in patientswith PSC compared with controls, and thiamine mono-
phosphate was reduced in PSC (Supplementary Figure 8C
and D). Plasma levels of these B vitamins did not correlate
with the relative abundance of associated metabolic path-
ways or enzyme families in the 27 patients with both
microbiome and metabolomics data available (data not
shown), possibly due to the long interval between sampling
of stool and plasma (median interval, 2.9 years). The
essential amino acid histidine was reduced in patients with
PSC compared with HCs (P ¼ .005, Supplementary
Figure 9A). Among other measured amino acids
(Supplementary Figure 9B–E), only ornithine was increased
in PSC (P ¼ .016).
Figure 4.Genetic potential of the gut microbiome in patients with PSC. Dot-plots showing relative abundance of enzyme
families (level-4 EC categories) related to microbial metabolism of BCAAs (A) valine, (B) leucine, and (C) isoleucine, (D) the
active form of vitamin B6 (PLP) and (E) the active forms of vitamin B2, flavin mononucleotide (FMN), and (F) flavin adenine
dinucleotide (FAD), and (G) synthesis of riboflavin (vitamin B2) and related metabolites, (H, I) ammonia production, and (J)
antibiotic resistance. Red bar marks the median. *Qfdr < .05; **Qfdr < .01; ***Qfdr < .001.




BILIARYAs circulating levels of BCAAs have been linked to the
potential ability of the gut microbiome to transport these
amino acids into bacteria,32 we specifically investigated 5
Kyoto Encyclopedia of Genes and Genomes orthologue gene
groups related to inward transportation of BCAAs into
bacteria. These gene groups showed markedly higher
abundance in PSC compared with HCs in the meta-analysis
(K01995 Qfdr ¼ .078; K01996, K01999, K01997, and
K01998 Qfdr < .05), and similar levels in IBD compared with
PSC (Supplementary Figure 10).
Microbial metabolites may modify the severity of dis-
eases.32 We therefore investigated the relationship between
metabolites and liver transplantation–free survival in PSC.
The plasma concentrations of PLP and all BCAAs (ie,
isoleucine, leucine, and valine) were lower in the patients
reaching an end point than in those who did not(Supplementary Figure 11). When dividing the plasma
concentrations into quartiles, low levels of these metabolites
all strongly predicted reduced liver transplantation–free
survival (Figure 5E–H). The effect seemed particularly
strong for PLP (Figure 5A and E), which was associated with
reduced risk of liver transplantation or death in a Cox
regression model, independent of Mayo risk score and
enhanced liver fibrosis score (hazard ratio, 0.66 per quartile
increase in plasma PLP; 95% confidence interval, 0.51–0.87;
P ¼ .003) (Supplementary Table 6). PLP was also associated
with reduced risk of liver transplantation or death inde-
pendent of other risk scores, that is, Amsterdam-Oxford
model for PSC (hazard ratio, 0.67 per quartile increase in
plasma PLP; 95% confidence interval, 0.51–0.88; P ¼ .003)
(Supplementary Table 7). PLP may be metabolized by
alkaline phosphatase,33 and the 2 showed a moderate
Figure 5.Microbiome-related plasma
metabolites and liver transplantation–
free survival. (A) The active vitamin B6
metabolite PLP, (B) isoleucine, (C)
leucine, and (D) valine in plasma of pa-
tients with PSC compared with HCs.
Kaplan-Meier plots showing that low
levels (first quartile) of (E) PLP, (F)
isoleucine, (G) leucine, and (H) valine
were all associated with reduced liver
transplantation–free survival in PSC.

















inverse correlation (r ¼ –.38, P < .001), but alkaline
phosphatase was not independently associated with sur-
vival when added to the model (Supplementary Table 6).Isoleucine, leucine, and valine were not independently
associated with liver transplantation–free survival when
corrected for Mayo risk score (data not shown).




BILIARYMicrobiome as Predictor of Disease Phenotypes
and Clinical Characteristics in Primary Sclerosing
Cholangitis
When applying a random forest model on the species
data, we were able to separate PSC from HCs with a high
predictive power (AUC ¼ 0.88 ± 0.04; Figure 6A) and ach-
ieved similar results when separating PSC from IBD (AUC ¼
0.83 ± 0.07; Figure 6B). Separating PSC from HCs and IBD at
the same time gave similar predictive power
(Supplementary Figure 12). Adding anthropometric infor-
mation (ie, age, sex, and body mass index) had minimal ef-
fect on the prediction of PSC vs HCs (AUC ¼ 0.87 ± 0.05,
Matthew’s correlation coefficient ¼ 0.54 ± 0.11;
Supplementary Figure 12), and using species data generally
performed better than enzyme families and metabolic
pathways for separating the phenotypes (Supplementary
Figure 12).
Finally, we merged the 2 microbiome cohorts for ana-
lyses of differences between clinical entities in patients with
PSC (n ¼ 136). Comparing patients with PSC with and
without IBD, we were unable to detect any differences in
gene richness (P ¼ .39, Supplementary Figure 3), species,
metabolic pathways, or enzyme families (all meta-analyses
Qfdr > .1; Supplementary File 1). Neither was there a sig-
nificant shift in overall bacterial composition between pa-
tients with PSC with and without IBD (Supplementary
Figure 13). There was no correlation between microbial
gene richness and disease duration in PSC (r ¼ .007, P ¼
.94, n ¼ 130) or the Mayo risk score (r ¼ –.07, P ¼ .63, n ¼
51). In a subset of the German patients with PSC (n ¼ 41)
with liver stiffness measurements available (measured by
transient elastography), liver stiffness did not show signif-
icant correlation with gene richness (r ¼ –.21, P ¼ .19).
When testing for associations of liver stiffness with enzyme
families and metabolic pathways related to vitamin B6 or
BCAA synthesis, there was a weak association between
increased liver stiffness and reduced levels of EC6.1.1.4
leucine transfer RNA ligase (r ¼ –.39, unadjusted P ¼ .012,
Supplementary Figure 14), but not for any other of the
tested functional features.
Ursodeoxycholic acid (UDCA) use in patients with PSC
was associated with higher levels of E rectale (estimate:
0.70, P ¼ .004, Qfdr ¼ .26; Supplementary File 1), which was
depleted in PSC compared with HCs in the meta-analyses
(Figure 2A). UDCA use was also associated with reduced
abundance of Veillonella dispar (estimate: –1.05, P ¼ .01,
Qfdr ¼ .34; Supplementary File 1). Furthermore, there was a
shift in b-diversity (Bray-Curtis) between UDCA users and
nonusers (R2 ¼ 0.030, P ¼ .005; Supplementary Figure 13).
We did not detect any significant effect by 5-aminosalicylic
acid (5-ASA) on any species (Qfdr > .50). Neither 5-ASA nor
UDCA use was associated with differences in enzyme fam-
ilies or metabolic pathways (all, Qfdr > .19). Notably, UDCA
use in PSC was only analyzed in the Norwegian cohort, as
94% (n ¼ 63) of the German patients with PSC were using
UDCA at the time of sampling.Discussion
In the present study, we analyzed the stool microbiome in
2 cohorts of Norwegian and German subjects comprising
patients with PSC, patients with IBD, and HCs. Using high-
resolution shotgun metagenomic sequencing and targeted
metabolomics in a third independent cohort of Norwegian
patients with PSC and HCs we uncovered a PSC-associated
microbiome with a low gene count and multiple bacterial
alterations unaffected by concurrent IBD, and which could
now be defined at species level; marked alterations of gene
functions related to, for example, vitamin B6 synthesis and
BCAA synthesis in the microbiome of PSC; reduced plasma
concentrations of vitamin B6 and BCAAs in PSC, and low
concentrations of these metabolites strongly associated with
reduced liver transplantation–free survival, suggesting that
investigating alteredmicrobialmetabolismmayhelppinpoint
biologic changes relevant for the disease course in PSC.
By using shotgun metagenomic sequencing, we make a
major leap forward in microbiome studies investigating PSC,
providing detailed functional analysis of microbial genes
encoding enzymes and metabolic pathways. Genes related to
bacterial synthesis of several essential nutrients like BCAAs
and vitamin B6 (eg, PLP) showed clear changes in patients
with PSC compared with HCs. PLP is the active form of
vitamin B6, an essential cofactor of numerous metabolic
reactions, and contributes to intestinal immune regulation
and lymphocyte trafficking into the intestines.34 PLP can be
produced de novo via 2 independent pathways. The pre-
dominant route used by the majority of organisms capable
of PLP production is via a single enzyme (EC4.3.3.6),30,31,35
which was markedly depleted in PSC. The less abundant,
multi-enzyme pathway PYRIDOXSYN-PWY: pyridoxal 5’-
phosphate biosynthesis was increased in PSC. Overall, the
data suggest a reduced genetic potential to synthesize PLP
in PSC, and calls for further evaluations in an experimental
model system. The capacity of the gut bacteria to synthesize
vitamin B6 has been estimated to meet 86% of the daily
recommended intake,31 suggesting that alterations in the
gut microbiome may dramatically influence dietary re-
quirements. Targeted metabolite analyses in plasma showed
reduced concentrations of both PLP and other B6 species
(pyridoxal and 4-pyridoxic acid), suggesting a true vitamin
B6 deficiency in PSC.36 Notably, PLP is known to be reduced
in end-stage liver disease of different etiologies,37 linked not
only to deficiency per se, but also due to increased catabo-
lism of PLP to pyridoxal, by for example, alkaline phos-
phatase or other mechanisms in the context of chronic
inflammation.38 Still, the predictive effect independent from
Mayo risk score could point to a role of PLP in PSC beyond
end-stage liver disease. Taken together, identification of
altered bacterial functions pointed us to important biology
that was altered also systemically. It should be emphasized
that we do not show a direct link between the gut and blood,
but additional studies should investigate such a link and
whether PLP represents a mechanism or only a marker of
disease activity and severity in PSC.
Figure 6. Separation of clinical phenotypes using random forest classification. (A) PSC vs HCs and (B) PSC vs IBD. Results
using all available species (red line) or only the significant species hits (blue line). F1, F1 measure; MCC, Matthew’s correlation
coefficient (range, –1 to þ1).

















Similar considerations regarding microbial synthesis and
dietary requirements are relevant for BCAAs. Circulating
BCAAs are known to be reduced in patients with cirrhosis,
but also less advanced liver diseases, including PSC.39,40 In
contrast, individuals with insulin resistance have been
shown to have elevated circulating BCAA levels, correlating
with increased synthesis capacity in the microbiome as well
as reduced capacity to import these BCAAs into bacteria.32
In PSC, we found the opposite, with reduced bacterial syn-
thesis and increased import capacity into bacteria. This calls
for consideration as to whether the gut microbiome con-
tributes to the observed reduced plasma BCAA concentra-
tions in PSC. Low plasma BCAA concentrations predicted
reduced liver transplantation–free survival in our study, but
not independently of the Mayo risk score, suggesting that
alterations in BCAAs may relate to disease stage. Firm
conclusions regarding the role of these metabolites in PSC in
humans would require an interventional trial with, for
example, supplementation,41 while the potential clinical
value of vitamin B6 or BCAAs as predictive biomarkers in
PSC would require independent validation studies. Notably,
because deficiencies of vitamin B6 and BCAAs have been
observed in liver diseases of several etiologies, similar gut
microbiome–related modifier effects may be seen also in
other liver diseases.37,42
For other measured metabolites, the relationship be-
tween the gut microbiome and plasma levels was less
obvious. For thiamine and riboflavin, this could perhaps be
explained by the low potential contribution from the gut
microbes, estimated to meet only 2%–3% of daily recom-
mended intake.31 However, the alterations in bacterial
genes related to riboflavin metabolism in PSC may be of
interest, because these are the source of bacterial riboflavinmetabolites that are essential in the activation of mucosal-
associated invariant T cells, which are liver-abundant
innate-like T cells relevant in PSC.43–45
Functional aspects of the gut microbiome are important,
but the actions of specific bacterial species are also of in-
terest. We observed an increase of the classical potential
pathogen Escherichia, together with reductions in species
typically classified as producers of the short-chain fatty acid
butyrate. Previous work has highlighted an increased rela-
tive abundance of the Veillonella genus in PSC.7 Veillonella
was less prevalent when investigated with the current
methodology, but we observed an increased prevalence of
several Veillonella species in patients with PSC. In a study by
Nakamoto et al,12 K pneumonia strains isolated from pa-
tients with PSC contributed to increased susceptibility to
hepatobiliary damage in mice and more bacterial trans-
location. In the shotgun sequencing data in the present
study, K pneumoniae showed higher prevalence in patients
with PSC compared with HCs, as reported by Nakamoto et al
in their study. Using a more sensitive method (quantitative
polymerase chain reaction) in a small subset of the German
cohort, K pneumoniae sequences were identified in a much
higher proportion of the patients with PSC compared with
the shotgun sequencing data, but with similar prevalence in
PSC and HCs. The clinical relevance of very low abundant
taxa, such as K pneumoniae, could be questioned, and the
role of K pneumoniae in human PSC is not well defined. As
the experimental data from the article by Nakamoto et al
suggest, it is possible that only specific strains of the K
pneumoniae species are capable of inducing hepatobiliary
damage, highlighting the need for increased resolution in
further microbiome research. Interestingly, a similar
concept was presented recently in patients with alcoholic




BILIARYhepatitis, who had higher frequency of fecal Enterococcus
faecalis.46 The presence of E faecalis strains with the ability
to produce the exotoxin cytolysin was associated with more
severe disease.46 Overall, it appears that both individual
microbes and shifts in the collective metabolic capacity of
the gut microbiome may modify human diseases without
necessarily being the triggering events. Such mechanisms
may point toward new treatment opportunities.
One important observation was the striking similarity
between the microbiome in patients with PSC with and
without IBD, both at species and functional level. In line
with previous data,2,3 the global microbiome composition in
IBD without liver disease was different from patients with
PSC. However, few species and functions were significantly
different between patients with PSC and patients with IBD
without PSC, suggesting that the differences separating PSC
from IBD relate to smaller changes in multiple species or
functions. Considering the microbiota literature, the differ-
ences between PSC and IBD are less consistent than be-
tween PSC and HCs.2,3,7 It is possible that the challenge of
appropriately matching patients with IBD with and without
PSC for case–control studies makes these comparisons
difficult.
Differences depending on geography impose another
challenge but might also be an important tool in case–
control studies. In addition, sampling and DNA extractions
were performed differently in the Norwegian and German
cohorts. Geography does, in some studies, constitute the
strongest predictor of microbiome composition,47 high-
lighting a need for identification and validation of core
features in multi-cohort international studies to define true
disease characteristics. However, in the present study, it is
not possible to assign with certainty differences between
Norway and Germany to geography or methodology.
The major strengths of this study are the use of 2 in-
dependent case–control cohorts from different countries
and the use of state-of-the art sequencing methods with
high taxonomic and functional resolution. Although this
study, to our knowledge, is the largest published so far to
investigate the microbiome in PSC using full metagenomic
sequencing, it is likely that by including additional patients
and also liver disease controls, the robustness of the results
could further increase. Notably, the link between our find-
ings of microbiome changes and differences in metabolites
and prognosis are, as of now, purely associative. Time- and
subject-matched blood and stool samples would be impor-
tant in further studies, in addition to experimental studies, if
these associations are to be further explored. Liver trans-
plantation as an end point could vary in different countries
and could make it less useful as an end point intended for
clinical translation. Another limitation is that dietary data
were only surveyed crudely through standard question-
naires, so it cannot be discounted that dietary factors could
have influenced our results. In addition, due to the cross-
sectional design, we are unable to discern whether the
changes we detect occur before or after disease onset, which
limits the possibility of drawing conclusions about cause or
effect. As PSC is a rare disease it is difficult, if not impossible,
to profile the microbiome over the time of disease onset.However, larger international cohorts with follow-up data
should be established to help address these knowledge gaps.
In conclusion, the gut microbiome of patients with PSC
exhibits large functional differences compared with HCs,
including microbial metabolism of essential nutrients, irre-
spective of the presence of IBD. Alterations in related
circulating metabolites associated with liver
transplantation–free survival suggest that overall microbial
functions may be relevant for the disease process in PSC.
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